Ignite Creation Date:
2025-12-24 @ 9:21 PM
Ignite Modification Date:
2025-12-28 @ 2:08 AM
Study NCT ID:
NCT06114004
Status:
RECRUITING
Last Update Posted:
2025-06-25
First Post:
2023-10-20
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Selinexor Plus Gemcitabine in Selected Advanced Soft-tissue Sarcoma (SeliSarc)
Sponsor:
Asociación Europea y Latinoamericana SELNET para la Investigación en Sarcomas
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-09-28
Start Date Type:
ACTUAL
Primary Completion Date:
2026-05-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-05-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-10-20
First Submit QC Date:
None
Study First Post Date:
2023-11-02
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-06-24
Last Update Post Date:
2025-06-25
Last Update Post Date Type:
ACTUAL